This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CD200	<p><i>In vitro</i> and mouse studies suggest anti-CD200 antibodies could help treat CD200-negative tumors, in addition to CD200-positive tumors. In a mouse model of skin tumors that do not express CD200, knocking out the target nevertheless lowered tumor number and delayed growth compared with those in wild-type controls. Next steps include testing anti-CD200 antibodies in mice with CD200-negative tumors. Alexion Pharmaceuticals Inc.'s samalizumab, an anti-CD200 mAb, is in Phase I/II testing to treat chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).</p> <p>SciBX 4(44); doi:10.1038/scibx.2011.1229 Published online Nov. 10, 2011</p>	Findings unpatented; unavailable for licensing	<p>Rygiel, T.P. <i>et al. Oncogene</i>; published online Oct. 24, 2011; doi:10.1038/onc.2011.477</p> <p>Contact: L. Meyaard, University Medical Center Utrecht, Utrecht, the Netherlands e-mail: l.meygaard@umcutrecht.nl</p>